Join Worldwide’s own Sherilyn Adcock, EVP of Medical and Scientific Affairs, as she discusses industry changes in Phase 1 Early development programs over recent years. Topics include:

  • Shifts in formal drug testing and approval processes
  • Combining of single and multiple ascending dose studies
  • Advanced statistical methodology